NASDAQ:CMND Clearmind Medicine (CMND) Stock Price, News & Analysis $6.58 -0.02 (-0.30%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$6.66 +0.08 (+1.14%) As of 10/9/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Clearmind Medicine Stock (NASDAQ:CMND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Clearmind Medicine alerts:Sign Up Key Stats Today's Range$6.35▼$6.9450-Day Range$5.72▼$15.6852-Week Range$5.25▼$3,840.00Volume9,064 shsAverage Volume39,681 shsMarket Capitalization$3.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Clearmind Medicine Inc. (NASDAQ: CMND) is a clinical-stage biotechnology company developing psychedelic-derived therapeutics for underserved health conditions. The company’s research focuses on creating proprietary compounds designed to address disorders involving addictive and compulsive behaviors. Clearmind’s lead research program centers on MEAI, a proprietary psychedelic molecule being evaluated for potential use in alcohol use disorder and binge-related behaviors. The company has also investigated additional applications for its compounds, including treatments for obesity and other conditions associated with abnormal consumption patterns. Clearmind advances its programs through preclinical research, intellectual-property development and clinical testing, with the goal of establishing new pharmaceutical treatments rather than providing psychedelic services directly. The company is headquartered in Israel and operates as a biotechnology developer serving the global pharmaceutical and healthcare markets.AI Generated. May Contain Errors. Read More Clearmind Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreCMND MarketRank™: Clearmind Medicine scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Clearmind Medicine. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearmind Medicine is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearmind Medicine is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearmind Medicine has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.40% of the float of Clearmind Medicine has been sold short.Short Interest Ratio / Days to CoverClearmind Medicine has a short interest ratio ("days to cover") of 0.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearmind Medicine has recently decreased by 58.53%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearmind Medicine does not currently pay a dividend.Dividend GrowthClearmind Medicine does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.61 News SentimentClearmind Medicine has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Clearmind Medicine this week, compared to 5 articles on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Clearmind Medicine insiders have not sold or bought any company stock.Percentage Held by Institutions96.05% of the stock of Clearmind Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Clearmind Medicine's insider trading history. Receive CMND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMND Stock News HeadlinesClearmind Gains Japan Patent Coverage For 3-MMC And PEA CombinationOctober 8 at 11:25 PM | rttnews.comClearmind Medicine Announces Japanese Patent Application Publication for 3-MMC-Based Dyskinesia Treatment, Including PEA CombinationsOctober 8 at 7:51 AM | quiverquant.comQReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 11 at 1:00 AM | Base Camp Trading (Ad)Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement DisorderOctober 8 at 7:32 AM | globenewswire.comClearmind Seeks Streamlined FDA Review For Neuroplastogen TherapiesOctober 7, 2026 | rttnews.comClearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDAOctober 7, 2026 | globenewswire.comClearmind Reports U.S. Patent Applications For Drug Combinations In Mental HealthSeptember 26, 2026 | rttnews.comClearmind Medicine Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine CombinationsSeptember 24, 2026 | marketscreener.comMSee More Headlines CMND Stock Analysis - Frequently Asked Questions How have CMND shares performed this year? Clearmind Medicine's stock was trading at $144.80 on January 1st, 2026. Since then, CMND shares have decreased by 95.5% and is now trading at $6.58. How were Clearmind Medicine's earnings last quarter? Clearmind Medicine Inc. (NASDAQ:CMND) posted its quarterly earnings results on Thursday, September, 10th. The company reported ($4.56) earnings per share (EPS) for the quarter. When did Clearmind Medicine's stock split? Clearmind Medicine shares reverse split on the morning of Tuesday, November 28th 2023.The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Clearmind Medicine IPO? Clearmind Medicine (CMND) raised $9 million in an initial public offering on Tuesday, November 15th 2022. The company issued 1,300,000 shares at $6.00-$8.00 per share. Aegis Capital Corp. served as the underwriter for the IPO. How do I buy shares of Clearmind Medicine? Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Clearmind Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clearmind Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), AppLovin (APP) and e.l.f. Beauty (ELF). Company Calendar Last Earnings9/10/2026Today10/11/2026Fiscal Year End10/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CMND's financial health is in the Red zone, according to TradeSmith. CMND has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CMND CIK1892500 Webwww.clearmindmedicine.com Phone604-260-1566FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($40.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-88.53% Return on Assets-61.62% Debt Debt-to-Equity Ratio0.01 Current Ratio4.31 Quick Ratio4.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$115.31 per share Price / Book0.06Miscellaneous Outstanding Shares510,000Free FloatN/AMarket Cap$3.36 million OptionableNot Optionable Beta0.93 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:CMND) was last updated on 10/9/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
